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Abstract
Rationale The clinical efficacy of the monoamine and
noradrenaline transporter inhibitors methylphenidate and
atomoxetine in attention deficit/hyperactivity disorder impli-
cates noradrenergic neurotransmission in modulating inhibi-
tory response control processes. Nonetheless, it is unclear
which adrenoceptor subtypes are involved in these effects.
Objectives The present study aimed at investigating the
effects of adrenoceptor agonists on inhibitory response
control as assessed in the rodent 5-choice serial reaction
time task, a widely used translational model to measure this
executive cognitive function.
Results Consistent with the previous reported effects of
atomoxetine, the noradrenaline transporter inhibitor desipra-
mine improved inhibitory response control, albeit the effect
size was smaller compared to that of atomoxetine. Methyl-
phenidate exerted a bimodal effect on inhibitory response
control. Interestingly, the preferential β2-adrenoceptor ago-
nist clenbuterol improved inhibitory response control.
Moreover, clenbuterol improved visuospatial attention in
thetask, aneffectthat was also observedwiththepreferential
β1-adrenoceptor agonist dobutamine. By contrast, although
the preferential α1-adrenoceptor and α2-adrenoceptor ago-
nists (phenylephrine and clonidine, respectively) and the
non-selective β-adrenoceptor agonist (isoprenaline) were
found to alter inhibitory response control, this was probably
secondary to the simultaneous increments in response
latencies and omissions observed at effective doses.
Conclusions Takentogether,thesefindingsfurtherstrengthen
the notion of noradrenergic modulation of inhibitory response
control and attentional processes and particularly reveal the
involvement of β2-adrenoceptors therein.
Keywords Adrenoceptors.Attention.Clenbuterol.
Impulsive behaviour.Noradrenaline.Rat
Introduction
Disturbances in inhibitory control over behaviour play a
central role in the symptomatology of attention deficit/
hyperactivity disorder (ADHD; Barkley 1997; Sonuga-Barke
2005). Neuroimaging studies have greatly contributed to our
growing understanding of the neural substrates of inhibitory
response control processes (Aron and Poldrack 2005) and the
observed structural and functional changes in the brains of
ADHD patients (Valera et al. 2007). In addition to human
preclinical approaches, much of our understanding of the
neural substrates of inhibitory response control is derived from
rodent lesion and neuropharmacological studies (Eagle et al.
2008; Pattij and Vanderschuren 2008;W i n s t a n l e ye ta l .2006).
Consistent with the therapeutic efficacy of the noradren-
aline (NA) transporter inhibitor atomoxetine in ADHD
patients (Chamberlain et al. 2007), recent studies have
demonstrated that atomoxetine also improves inhibitory
response control in several translational rodent models
(Bari et al. 2009; Blondeau and Dellu-Hagedorn 2007;
Robinson et al. 2008). Thus, these findings implicate
noradrenergic neurotransmission in modulating inhibitory
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DOI 10.1007/s00213-011-2405-2response control processes, although the precise mechanisms
underlying these effects are not fully understood. Early
neuronal recording experiments and subsequent studies in
laboratory animals have shown that NA neurons of the locus
coeruleus (LC) are phasically discharged upon exposure to
novel, salient and arousing environmental stimuli (see for
example, Aston-Jones and Bloom 1981; Foote et al. 1980;
Sara et al. 1994). This phasic activity of the LC NA system
might promote processing of these stimuli in upstream
projection areas, including cortical areas, and thereby facilitate
the preparation of subsequent appropriate behavioural
responses. In addition, moderate tonic activity of the LC has
beenassociatedwithoptimalbehaviouralperformance(Aston-
Jones et al. 1999). In the rodent brain, frontal cortical areas
importantly modulate inhibitory response control processes
(Chudasama et al. 2003) and furthermore receive afferent
projections from the LC (for review see, Foote and Morrison
1987). In turn, frontal cortical areas might modulate activity
of the LC via efferent projections (Jodo et al. 1998;S a r aa n d
Herve-Minvielle 1995). Collectively, this has led to the view
that the NA system—perhaps acting in concert with the
dopaminergic system—plays a key role in optimizing behav-
ioural responses including prefrontal cortical and executive
cognitive function (Arnsten 2000; Aston-Jones and Cohen
2005;S a r a2009). Considering the current working hypoth-
esis on noradrenergic functioning, this might also explain the
therapeutic efficacy of methylphenidate in ADHD, which has
been shown to enhance NA levels at low doses (Berridge et
al. 2006; Devilbiss and Berridge 2006).
To date, little is known with regard to the involvement of
different adrenoceptor subtypes in inhibitory response
control, although previous work in rodents suggested a
functional role of α-adrenoceptors (Milstein et al. 2007;
Puumala et al. 1997; Ruotsalainen et al. 1997; Sirvio et al.
1994). Generally, these studies suggest α1-adrenoceptor
involvement, as an agonist of this adrenoceptor subtype
was found to selectively improve inhibitory response
control (Puumala et al. 1997). Moreover, α2-adrenoceptor
agonists also ameliorate inhibitory response control, albeit
these beneficial effects were only observed at doses that
simultaneously impaired somatomotor performance (Milstein
et al. 2007; Ruotsalainen et al. 1997; Sirvio et al. 1994).
Thus, these preclinical findings with α-adrenoceptor agonists
in part support the clinical beneficial effects of the α2-
adrenoceptor agonists clonidine and guanfacine in ADHD
(Arnstenetal.2007). Interestingly, in both healthy volunteers
and rats, the α2-adrenoceptor antagonist yohimbine has been
demonstrated to impair inhibitory response control (Sun et
al. 2010; Swann et al. 2005). To our knowledge, β-
adrenoceptor involvement in inhibitory response control has
not been investigated in detail before. Therefore, further
dissecting the contribution of specific adrenoceptors therein
could provide novel insights into the mechanism of action of
atomoxetineandmethylphenidate.Tothatend,weinvestigated
the effects of various selective α-adrenoceptor and β-
adrenoceptor agonists in addition to those of indirect agonists
on inhibitory response control in rats. More specifically, we
tested the effects of the monoamine reuptake inhibitor
methylphenidate, the noradrenaline reuptake inhibitor
desipramine, the α1-adrenoceptor and α2-adrenoceptor
agonists phenylephrine and clonidine, the non-selective
β-adrenoceptor agonist isoprenaline and lastly the β1-
adrenoceptor and β2-adrenoceptor agonists, dobutamine
andclenbuterol.Toassessdrugeffects,ratsweretrainedinthe
5-choiceserialreactiontimetask(5CSRTT),whichisawidely
employed rodent operant cognitive task adopted from the
human continuous performance task that measures aspects of
visuospatial attention as well as inhibitory response control
(see for reviews, Bari et al. 2008;R o b b i n s2002).
Material and methods
Subjects
In total, 60 male Wistar rats were obtained from Harlan CPB
(Horst, The Netherlands). At the start of the experiments,
animals were 12 weeks old, weighed approximately 250 g and
were housed in pairs in macrolon cages (42.5×26.6×18.5 cm;
l × w × h) under a reversed 12-h light/dark cycle (lights on at
7:00 p.m.) at controlled room temperature (21±2°C) and
relative humidity of 60±15%. Animals were maintained at
approximately 90% of their free-feeding weight, starting
1 week prior to the beginning of the experiments by restricting
the amount of standard rodent food pellets (Harlan Teklad
Global Diet, Blackthorn, UK). Water was available ad libitum
throughout the entire experiment. All experiments were
conducted with the approval of the animal ethical committee
of the Vrije Universiteit, Amsterdam, the Netherlands.
Apparatus
Experiments were conducted in identical rat five hole nose
poke operant chambers with stainless steel grid floors (MED-
NPW-5L, Med Associates Inc., St. Albans, VT, USA) housed
in sound-insulating and ventilated cubicles. Set in the curved
wall of each box was an array of five holes. Each nose poke
unit was equipped with an infrared detector and a yellow light
emitting diode stimulus light. Rodent food pellets (45 mg,
FormulaP, Bio-Serv, Frenchtown,USA) could bedelivered at
the oppositewallvia a dispenser andawhitehouse lightcould
illuminate the chamber. A computer equipped with MED-PC
version 1.17 (Med Associates Inc.) controlled experimental
sessions and recorded data. The animals were tested once
daily from Monday until Friday during the dark phase of the
light/dark cycle.
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To habituate animals to the operant chambers, rats were
exposed to the operant chambers for 20 min with the
houselight on and the food cup containing three food pellets
for two consecutive sessions. Subsequently, in the next two
sessions, pellets (100 per session) were delivered with an
average delay of 15 s to allow the animals to associate the
sound of pellet delivery with reward. Following this, the
rats were trained in the 5CSRTT paradigm. A detailed
description of the 5CSRTT behavioural procedure in our
laboratory has been provided previously (Van Gaalen et al.
2006a). In short, rats were trained to detect and respond to a
brief visual stimulus in one of five nose poke units in order
to obtain a food reward. Each session terminated after 100
trials or 30 min, whichever occurred first. Initially, the
duration of this stimulus was 32 s and was gradually
decreased to 1 s over sessions until animals reached stable
baseline performance (accuracy >80% correct choice and
<20% errors of omission, for at least five consecutive
sessions). Responding during stimulus presentation or
within the limited hold (LH) period of 2 s was counted as
a correct response. Incorrect, premature responses during
the fixed 5-s intertrial interval and errors of omission (no
responses or a response after the LH) did not lead to the
delivery of a food reward and resulted in a 5-s time out
period during which the houselight was extinguished,
whereas perseverative responses, i.e. repeated responding
during the presentation of the stimulus, were measured but
did not have any programmed consequences. Two different
measures of inhibitory control were measured, namely (1)
the percentage of premature responses before stimulus
onset, calculated as number of premature responses = ½
correct þ incorrect þ omitted trials ðÞ     100 and (2) the
percentage of perseverative responses into the stimulus
unit after correct choice, a measure of compulsive behav-
iour, calculated as number of perseverative responses = ½
correct þ incorrect þ omitted trials ðÞ     100. In addition,
the following other behavioural parameters were measured
that reflect task performance, namely (3) accurate choice,
i.e. percentage correct responses calculated as number ½
correct trials = correct þ incorrect trials ðÞ     100;( 4 )l a -
tency to make a correct choice, i.e. the mean time between
stimulus onset and nose poke in the illuminated unit; (5)
omission errors, i.e. the percentage of omitted trials during a
session calculated as number of omitted trials = correctþ ð ½
incorrect þ omitted trialsÞ    100 and (6) feeder latency,
i.e. the latency to collect a pellet following correct choice.
Drugs
Methylphenidate hydrochloride (Fagron, Nieuwerkerk a/d
IJssel, Netherlands), clenbuterol hydrochloride, desipra-
mine hydrochloride, dobutamine hydrochloride, phenyleph-
rine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA),
clonidine hydrochloride (Boehringer Ingelheim, Ingelheim
am Rhein, Germany) and isoprenaline sulphate (ACF
Chemiefarma, Maarssen, the Netherlands) were dissolved
in sterile saline. All drugs were injected 30 min before
testing, with the exception of methylphenidate, isoprenaline
and clenbuterol that were injected 20 min before testing.
Desipramine (dose range, 1–10 mg/kg), clenbuterol (dose
range, 0.01–0.1 mg/kg), dobutamine (dose range, 1–6m g / k g )
and phenylephrine (dose range, 0.3–3 mg/kg) were injected
intraperitoneally,clonidine(doserange,0.01–0.03mg/kg)and
isoprenaline (dose range, 0.1–1 mg/kg) were injected subcu-
taneously and methylphenidate (dose range, 1–10 mg/kg) was
administered orally via oral gavage. In group 1 (n=14), the
order of testing drugs was (1) desipramine, (2) clonidine and
(3) phenylephrine. In group 2 (n=14), isoprenaline was
tested; in group 3 (n=16), methylphenidate was tested, and
in group 4 (n=16), dobutamine and clenbuterol were tested.
Drugs were freshly prepared before testing and injected in a
volume of 1 ml/kg body weight according to a Latin square
within-subjects design on Tuesdays and Fridays with baseline
training sessions on the other weekdays. Drug doses were
based on previous reports employing instrumental behaviour
paradigms (Arnsten and Dudley 2005; Munzar and Goldberg
1999;O ’Donnell 1990; Van Gaalen et al. 2006b).
Statistical analyses
Data were subjected to repeated measures analysis of
variance (ANOVA) with drug dose as within-subjects
variable using the Statistical Package for the Social Sciences
version14 (SPSS Inc., Chicago, IL, USA). The homogeneity
of variance across groups was determined using Mauchly’s
tests for equal variances and in case of violation of
homogeneity, Huynh–Feldt epsilon (ε) adjusted degrees of
freedom were applied and the resulting more conservative
probability values were depicted and used for subsequent
analyses. In case of statistically significant main effects,
further post hoc comparisons were conducted using
Newman–Keuls multiple comparison tests. The level of
probability for statistically significant effects was set at 0.05.
Results
Baseline performance
Drug testing commenced upon stable baseline performance in
the 5CSRTT. Repeated measures ANOVA of the five last
baseline training sessions revealed that in all groups behav-
ioural performance had stabilized before drug testing in terms
of the percentage of accurate choice [group 1, F(4,52)=1.40,
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0.63, ε=0.43, p=0.52; group 4, F(4,60)=1.25, p=0.30], the
percentage of omission errors [group 1, F(4,52)=1.37, p=
0.26; group 2, F(4,52)=2.06, ε=0.71, p=0.12; group 3,
F(4,60)=0.65, p=0.63; group 4, F(4,60)=1.01, ε=0.78, p=
0.40] and the percentage of premature responding [group 1,
F(4,52)=1.14, p=0.35; group 2, F(4,52)=0.30, ε=0.60, p=
0.75; group 3, F(4,60)=1.06, ε=0.59, p=0.37; group 4,
F(4,60)=1.79, ε=0.59, p=0.18]. Furthermore, during testing
of all separate drugs, repeated measures ANOVA on the
intervening pre-drug baseline training sessions revealed that
behavioural performance on accurate choice, percentage
omissions and percentage premature responding did not shift
and remained stable (all p>0.05; data not shown).
Methylphenidate
Methylphenidate had a biphasic effect on the percentage
premature responses [Fig. 1a; F(3,45)=15.72, ε=0.47, p<
0.001] and strongly tended to decrease premature responding
at the low dose (1 mg/kg; p=0.055), whereas it increased this
parameter at the highest dose (10 mg/kg; p=0.002) com-
pared to vehicle. Accurate choice was decreased by
methylphenidate [Fig. 1b; F(3,45)=5.33, p=0.003], and
methylphenidate also speeded correct response latencies
[Fig. 1c; F(3,45)=3.28, p=0.029]. Further comparisons
revealed that only 10 mg/kg methylphenidate impaired
visuospatial attention (p=0.001) and speeded response
latencies (p=0.035) compared to the vehicle. The percentage
of omissions was not altered by methylphenidate [Fig. 1d;
F(3,45)=0.63, p=0.60] or was the percentage of persevera-
tive responses and latency to collect reward after correct
choice[Table1; F(3,45)=0.61, ε=0.53,p=0.51andF(3,45)=
0.40, ε=0.73, p=0.69, respectively].
Desipramine
The selective NA reuptake inhibitor desipramine dose
dependently decreased the percentage of premature
responses [Fig. 2a; F(3,39)=8.51, p<0.001] and further
analyses revealed that compared to vehicle this was the case
for both the 3 and 10 mg/kg dose of desipramine (p=0.022
and p<0.001, respectively). In addition to the effects of
desipramine on premature responding, desipramine in-
creased correct response latencies [Fig. 2c; F(3,39)=4.46,
p=0.009] and the percentage of omissions [Fig. 2d; (3,39)=
6.85, ε=0.85, p=0.002]. Further analyses revealed that only
10 mg/kg desipramine significantly increased response
latencies and omissions compared to the vehicle (p=0.005
and p<0.001, respectively). Likewise, the latency to collect
reward after correct choice was increased by desipramine
[Table 1; F(3,39)=3.37, ε=0.79, p=0.04]. Further analyses
Fig. 1 Methylphenidate exerts a
bimodal effect on the percentage
premature responses (a),
decreases the percentage correct
choice (b), shortens correct re-
sponse latency (c) and does not
affect the percentage omissions
(d) in the 5CSRTT. All data
are expressed as mean±SEM.
*p<0.05 and **p<0.005 com-
pared to vehicle treatment
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collection latencies compared to vehicle (p=0.049 and p=
0.008, respectively). Accurate choice was not affected by
desipramine [Fig. 2b; F(3,39)=0.31, p=0.82] or was the
percentage of perseverative nose pokes after correct choice
[Table 1; F(3,39)=0.85, p=0.48].
Phenylephrine
The α1-adrenoceptor agonist phenylephrine decreased the
percentage of premature responses [Fig. 3a; F(3,39)=6.97,
p=0.001] and this occurred only at the dose of 3.0 mg/kg
compared to the vehicle (p<0.001). Phenylephrine also
increased the latency to make a correct choice [Fig. 3c;
F(3,39)=10.72, ε=0.49, p=0.002] and increased the
percentage of omissions [Fig. 3d; F(3,39)=4.77, ε=0.55,
p=0.025]. Further comparisons showed that 3.0 mg/kg
phenylephrine significantly slowed response speed and
increased omission rate compared to vehicle (p=0.007 and p=
0.016, respectively). Moreover, phenylephrine significantly
improved accurate choice [Fig. 3b; F(3,39)=2.92, p=0.046].
Further comparisons revealed that the high dose of 3.0 mg/kg
phenylephrine tended to improve accurate choice compared
to the vehicle, yet this effect did not reach statistical
significance (p=0.063). The percentage of perseverative nose
pokes and latency to collect reward after correct choice were
not altered by phenylephrine [Table 1; F(3,39)=1.52, p=0.22
and F(3,39)=2.16, ε=0.65, p=0.14, respectively].
Clonidine
The α2-adrenoceptor agonist clonidine reduced the per-
centage of premature responses [Fig. 3e; F(2,26)=8.47, p=
0.001], and further analyses revealed that both doses
decreased premature responding compared to vehicle (both
p=0.008). In addition, clonidine dose dependently length-
ened the latency to make a correct response [Fig. 3g;
F(2,26)=40.54, p<0.001] at both doses compared to the
vehicle (both p<0.001). Clonidine also dose dependently
increased the percentage of omissions [Fig. 3h; F(2,26)=
42.25, p<0.001], and both doses increased omission rate
compared to vehicle (both p<0.001). The percentage of
perseverative responsesaftercorrect choicewas significantly
reduced by clonidine [Table 1; F(2,26)=3.68, p=0.039].
Further analyses showed that only 0.03 mg/kg clonidine
reduced the number of persevative nose pokes after correct
choice compared to vehicle treatment (p=0.031). Clonidine
did neither affect accurate choice [Fig. 3f; F(2,26)=1.29,
p=0.29] nor the latency to collect reward after correct
choice [Table 1; F(2,26)=1.40, ε=0.63, p=0.26].
Isoprenaline
The non-selective β-adrenoceptor agonist isoprenaline
reduced the percentage of premature responses [Fig. 4a;
F(3,39)=3.98, p=0.014]. Further analyses showed that
0.3 mg/kg isoprenaline reduced premature responding
compared to vehicle (p=0.024). Isoprenaline dose depen-
dently lengthened the latency to make a correct response
[Fig. 4c; F(3,39)=17.11, p<0.001] and further comparisons
revealed that all doses lengthened the latency compared to the
vehicle (0.1 and 1.0 mg/kg, both p<0.001 and 0.3 mg/kg, p=
0.002). The percentage of omissions was increased by
isoprenaline [Fig. 4d; F(3,39)=6.80, p=0.001] at all doses
compared to vehicle (0.1 mg/kg, p=0.002; 0.3 mg/kg, p=
0.003 and 1.0 mg/kg, p<0.001). Furthermore, isoprenaline
also lengthened the latency to collect reward after correct
Table 1 Effects of indirect and direct adrenoceptor agonists on the
percentage of perseverative responses and latencies to collect food
reward after correct choice
Drug Dose
(mg/kg)
Perseverative
responses (%)
Feeder
latency (s)
Methylphenidate 0 3.81±1.16 0.90±0.04
1.0 3.69±1.13 0.92±0.05
3.0 5.69±1.63 0.94±0.06
10.0 5.12±2.23 0.88±0.06
Desipramine 0 6.64±1.50 0.99±0.07
1.0 9.00±2.26 1.23±0.15*
3.0 8.93±1.38 1.06±0.06
10.0 9.86±1.61 1.25±0.12*
Phenylephrine 0 7.43±1.48 0.98±0.07
0.3 7.50±1.73 1.08±0.16
1.0 10.21±2.23 0.91±0.04
3.0 7.36±1.58 1.15±0.10
Clonidine 0 9.21±2.25 1.09±0.10
0.01 9.86±2.41 1.36±0.22
0.03 4.21±0.71* 1.19±0.06
Isoprenaline 0 5.29±2.53 0.98±0.05
0.1 2.64±0.84 1.10±0.07
0.3 4.21±1.44 1.07±0.05
1.0 4.57±2.08 1.19±0.08*
Dobutamine 0 12.54±7.24 1.21±0.13
1.0 9.23±4.10 1.31±0.12
3.0 8.08±2.70 1.16±0.11
6.0 4.77±1.67 1.25±0.13
Clenbuterol 0 7.53±2.14 1.27±0.16
0.01 7.07±1.75 1.33±0.14
0.03 8.60±1.65 1.45±0.13
0.1 6.40±1.39 1.82±0.25
Drug doses are expressed in milligrams per kilogram and all data are
expressed as the mean±SEM
*p<0.05 versus vehicle
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was only the case at 1.0 mg/kg compared to the vehicle (p=
0.023). Accurate choice [Fig. 4b; F(3,39)=1.04, p=0.39] and
the percentage of perseverative responses after correct choice
[Table 1; F(3,39)=0.76, p=0.53] were not affected by
isoprenaline.
Dobutamine
Three animals were excluded from all analyses, as these
individuals consistently omitted over 50 trials in all drug
dose treatments including vehicle treatment. Challenges
with the β1-adrenoceptor agonist dobutamine tended to
decrease the percentage of premature responses, although
the main dose effect did not reach statistical significance
[Fig. 5a; F(3,36)=3.21, ε=0.66, p=0.059]. Dobutamine did
increase the percentage of omissions [Fig. 5d; F(3,36)=
4.25, p=0.011] and further comparisons revealed that only
3 mg/kg dobutamine increased the omission rate com-
p a r e dt ot h ev e h i c l e( p=0.002). In addition, dobutamine
improved accurate choice [Fig. 5b; F(3,36)=4.14, p=
0.013], and further analyses revealed that 6 mg/kg dobut-
amine improved visuospatial attention compared to the
vehicle (p=0.001). The latencies to make a correct choice
[Fig. 5c; F(3,36)=2.06, p=0.12] and collect food reward
after correct choice [Table 1; F(3,36)=1.06, ε=0.57, p=0.36]
were not altered by dobutamine or was the percentage of
perseverative responses [Table 1; F(3,36)=1.53, ε=0.47,
p=0.24].
Clenbuterol
One animal was excluded from all analyses due to a
consistent high number of omissions during vehicle and
drug treatments (>50 trials). The administration of the
selective β2-adrenoceptor agonist clenbuterol reduced the
percentage of premature responses [Fig. 5e; F(3,42)=6.48,
ε=0.73, p=0.004], and further comparisons showed that all
doses of clenbuterol decreased premature responding
compared to vehicle (0.01 mg/kg, p=0.036; 0.03 mg/kg,
p=0.008 and 0.1 mg/kg, p=0.009). Likewise, clenbuterol
lengthened the latency to make a correct response
[Fig. 5g; F(3,42)=10.31, ε=0.81, p<0.001] at the
0.1 mg/kg dose compared to the vehicle (p<0.001).
Clenbuterol also increased the percentage of omissions
[Fig. 5h; F(3,42)=19.16, ε=0.38, p<0.001] and this also
only occurred at the highest dose of 0.1 mg/kg compared
to the vehicle (p=0.001). Accurate choice was dose
dependently improved by clenbuterol [Fig. 5f; F(3,42)=
6.35, p=0.001], and both 0.03 and 0.1 mg/kg clenbuterol
increased the percentage correct choice compared to
vehicle (p=0.002 and p=0.005, respectively). The per-
Fig. 2 The noradrenaline
reuptake inhibitor desipramine
decreases the percentage prema-
ture responses (a), does not
affect the percentage correct
choice (b), and increases both
correct response latency (c) and
the percentage omissions (d)i n
the 5CSRTT. All data are
expressed as mean±SEM.
*p<0.05 and **p<0.005 com-
pared to vehicle treatment
332 Psychopharmacology (2012) 219:327–340centage of perseverative responses after correct choice and
the latency to collect food reward were not affected by
clenbuterol [Table 1; F(3,42)=0.45, p=0.72 and F(3,42)=
2.82, ε=0.51, p=0.094; respectively].
Fig. 3 The preferential
α1-adrenoceptor and α2-adre-
noceptor agonists phenylephrine
and clonidide decrease the per-
centage premature responses
(a, e), do not affect the percent-
age correct choice (b, f), and
increase correct response latency
(c, g) and the percentage omis-
sions (d, h) in the 5CSRTT.
All data are expressed as
mean±SEM. *p<0.05 and
**p<0.005 compared to vehicle
treatment
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The present data are consistent with a functional role of
noradrenergic transmission in inhibitory response control
processes. In particular, the NA reuptake inhibitor desipra-
mine was found to improve inhibitory response control at a
dose that did not affect somatomotor activity. Likewise,
methylphenidate seemed to have a similar effect at a low
dose, whereas opposite effects were found at higher doses
that impaired inhibitory response control by increasing
premature responding. Both the selective α1-adrenoceptor
and α2-adrenoceptor agonists (phenylephrine and cloni-
dine) and the non-selective β-adrenoceptor agonist (iso-
prenaline) tested in the present study were found to alter
inhibitory control, but these effects were only observed at
doses that simultaneously increased response latencies and
omission rate. By contrast, the selective β2-adrenoceptor
agonist clenbuterol, and to a lesser extent the β1-agonist
dobutamine, had beneficial effects on inhibitory control and
visuospatial attention at doses that did not alter other
behavioural parameters in the task.
The current findings with methylphenidate confirm
earlier data indicating that methylphenidate increases
impulsivity in the 5CSRTT (Milstein et al. 2010; Navarra
et al. 2008; Puumala et al. 1996; Van den Bergh et al. 2006).
Thus, in the present study, oral administration of 10 mg/kg
methylphenidate also robustly increased premature
responding. As methylphenidate increases monoamine
neurotransmission by inhibiting the activity of monoamine
transporter proteins (Rothman and Baumann 2003), it has
been well established that methylphenidate enhances both
dopaminergic and noradrenergic transmission in cortico-
striatal brain regions (Gerasimov et al. 2000; Kuczenski and
Segal 1997). In support of this, a large body of evidence
has demonstrated that elevating dopamine (DA) signalling
by means of the psychostimulant amphetamine or the
selective DA reuptake inhibitor GBR12909 robustly
increases premature responding in the 5CSRTT (Cole and
Robbins 1987; Harrison et al. 1997; Pattij et al. 2007;V a n
Gaalen et al. 2006a), possibly explaining the current
observations with 10 mg/kg methylphenidate. By contrast,
in the present study, a low oral dose of methylphenidate
(1 mg/kg) tended to reduce the number of premature
responses (p=0.055). Interestingly, comparable low doses
of methylphenidate have been shown to preferentially
increase the extracellular levels of NA over DA in the
prefrontal cortex and simultaneously improve sustained
attention and working memory (Berridge et al. 2006). This
could explain the beneficial effect of the low dose
methylphenidate on inhibitory control in the current study.
Indeed, enhancing NA transmission by the NA reuptake
inhibitor atomoxetine improves inhibitory response control
Fig. 4 The non-selective β-
adrenoceptor agonist isoprena-
line decreases the percentage
premature responses (a), does
not affect the percentage correct
choice (b), and increases correct
response latency (c) and per-
centage of omissions (d) in the
5CSRTT. All data are expressed
as mean±SEM. *p<0.05 and
**p<0.005 compared to vehicle
treatment
334 Psychopharmacology (2012) 219:327–340both in humans (Chamberlain et al. 2009) and laboratory
animals (Bari et al. 2009; Blondeau and Dellu-Hagedorn
2007; Paterson et al. 2011; Robinson et al. 2008). In
keeping with these findings, the selective NA transporter
Fig. 5 Effects of the β1 adre-
noceptor agonist dobutamine
and β2-adrenoceptor agonist
clenbuterol on the percentage
premature responses (a, e), per-
centage correct choice (b, f),
correct response latency (c, g)
and the percentage omissions
(d, h) as measured in the
5CSRTT. Both dobutamine and
clenbuterol improve visuospatial
attention at doses that do not
alter response latency or the
percentage of omitted trials. In
addition, clenbuterol exerts a
beneficial effect on inhibitory
response control by reducing the
percentage premature respond-
ing. All data are expressed as
mean±SEM. *p<0.05 and
**p<0.005 compared to vehicle
treatment
Psychopharmacology (2012) 219:327–340 335inhibitor desipramine also reduced the number of premature
responses at 3 mg/kg without affecting other behavioural
parametersinthe5CSRTT,althoughtheeffectsizewassmaller
compared to the findings with atomoxetine in this same
paradigm (Blondeau and Dellu-Hagedorn 2007; Paterson et
al. 2011;R o b i n s o ne ta l .2008). Collectively, these data thus
confirm the beneficial effects of elevating NA transmission
on inhibitory response control in addition to other executive
functions such as attentional set-shifting, behavioural flexi-
bility and working memory (Berridge et al. 2006; Lapiz et al.
2007; Seu et al. 2009) and this could underlie the therapeutic
efficacy of atomoxetine and methylphenidate.
Given the results obtained with methylphenidate and
desipramine, subsequent experiments were aimed at further
exploring the possible contribution of α-adrenoceptors and
β-adrenoceptors to modulate inhibitory response control. In
this regard, previous work in rats and monkeys have
implicated prefrontal cortical α2-adrenoceptor involvement
in the beneficial effects of methylphenidate and atom-
oxetine on working memory (Arnsten and Dudley 2005;
Gamo et al. 2010). To this aim, we tested the effects of
phenylephrine, clonidine and isoprenaline. Whereas all of
these compounds seemed effective in reducing premature
responding, this only appeared to occur at doses that also
strongly affected other behavioural parameters reflecting
task performance, hampering a straightforward interpreta-
tion of these findings. Most prominently, the doses of these
compounds reducing premature responding also increased
the errors of omission and lengthened response latencies.
These observations indicate that the effects on inhibitory
response control may be secondary to general behavioural
changes, e.g. somatomotor-suppressive effects or altered
motivation. On the other hand, the observation that the
highest dose isoprenaline increased the omissions and the
response latencies but not premature responding might
argue against such an interpretation. Our current findings
are supported by previous studies, in which direct adreno-
ceptor agonists have been reported to lead to general
behavioural alterations including lengthening of response
latencies and increments in response omissions in instru-
mental behaviour (for example see, Jentsch et al. 2009;
Mair et al. 2005; Marrs et al. 2005). More relevant to our
findings, the α2-adrenoceptor agonists dexmedetomidine
and guanfacine were also found to decrease premature
responding in the 5CSRTT at doses that simultaneously
increased omission rates (Ruotsalainen et al. 1997; Sirvio et
al. 1994) or lengthened latencies to collect food reward
(Milstein et al. 2007). Thus, consistent with these observa-
tions, a similar behavioural profile was obtained with
clonidine in the current study. Although we did not test
the lower doses of clonidine, previous work employing
such lower doses in a different instrumental behaviour task
reveals that the therapeutic window of this compound is
narrow and associated with response rate suppressive
effects (Dekeyne and Millan 2006).
The beneficial effects of α2-adrenoceptor agonists such
as clonidine and guanfacine on prefrontal cortical cognitive
functions in preclinical as well as clinical models are
thought to be primarily mediated through postsynaptic α2-
adrenoceptor activation in the prefrontal cortex (Arnsten
2000; Arnsten et al. 2007). By contrast, presynaptic α2-
adrenoceptor activation is well known to decrease NA
transmission (for review see, Berridge and Waterhouse
2003). In addition, α2-adrenoceptor agonists also have
strong hypnotic/sedative effects that are presumably
mediated in the basal forebrain, locus coeruleus and
thalamus (e.g. Berridge and Foote 1996; Buzsaki et al.
1991; Mizobe et al. 1996). Since all compounds were
administered peripherally, it is at present difficult to disentan-
gle the effects of clonidine on prefrontal cortical cognitive
function from its somatomotor effects as this would require
intracranial administration approach. Thus, while clonidine
seemedtoimprove inhibitoryresponsecontrol consistentwith
earlier data (Milstein et al. 2007; Ruotsalainen et al. 1997;
Sirvio et al. 1994) and the clinical therapeutic efficacy of α2-
adrenoceptor agonists (Arnsten et al. 2007), central actions
of clonidine on sedation/hypnosis are difficult to rule out. In
contrast to the effects of clonidine on inhibitory response
control, increasing activity at α2-adrenoceptors did not
improve visuospatial attention contrasting earlier findings
(Berridge et al. 2006; Jentsch et al. 2009; Paine et al. 2007;
Sagvolden 2006). However, in the current study, animals
were tested under standard task conditions with presumably
“optimal” levelsof attentional performance and noradrenergic
tone. In this regard, there are indications that the beneficial
effects of an elevated noradrenergic tone might particularly
become apparent under conditions of poor performance or
lower baseline noradrenergic tone (Jentsch and Anzivino
2004; Jentsch et al. 2009; Milstein et al. 2007).
The effects ofphenylephrine arepartlyinline withprevious
data demonstrating that the α1-adrenoceptor agonist St-587
improved both inhibitory response control and visuospatial
attention (Puumala et al. 1997). These beneficial effects of St-
587 on visuospatial attention and not inhibitory response
control could be antagonized by the α1-adrenoceptor
antagonist prazosin. This suggests particular involvement of
these receptor subtypes in attention, for instance by their role
in increasing vigilance (Sirvio and MacDonald 1999)a n di s
consistent with the view that α1-adrenoceptor activation
enhances the signal-to-noise ratio and tunes processing of
sensory information through subcortical and sensory cortical
regions (for reviews see, Arnsten 2000; Berridge and
Waterhouse 2003). Accordingly, phenylephrine improved
accurate choice, albeit separate post hoc comparisons on the
high-dose phenylephrine (3.0 mg/kg) failed to reach statistical
significance (p=0.063). The effects of phenylephrine on
336 Psychopharmacology (2012) 219:327–340premature responding occurred in concert with effects on
response latencies and omission rate and may therefore will
be secondary to its effects on somatomotor activity.
In addition to the well-known involvement of β-
adrenoceptors in memory consolidation processes (for review
see, Sara 2009), until now few studies have examined the role
of these receptors in executive cognitive functioning, namely
working memory. Inasmuch one can draw conclusions from
these initial studies, they suggest an opposing modulatory
role of β1-adrenoceptors and β2-adrenoceptors in working
memory. While a β1-adrenoceptor agonist deteriorates
w o r k i n gm e m o r y( R a m o se ta l .2005), a β2-adrenoceptor
agonist was found to improve working memory performance
(Ramos et al. 2008). Interestingly, recent work showed that
the non-selective β-adrenoceptor antagonist propanolol atten-
uated the detrimental effects ofmethylphenidate on premature
responding in the 5CSRTT (Milstein et al. 2010). This
suggests that methylphenidate impairs inhibitory response
control partly through β-adrenoceptor activation at a dose
elevating both NA and DA transmission. To our knowledge,
the present study is the first reporting on the behavioural
effects of β-adrenoceptor agonists in the 5CSRTT.
Whereasthenon-selective β-adrenoceptoragonist isopren-
aline did reducepremature respondingat0.3mg/kg,thissame
dose simultaneously increased omission rate and response
latencies comparable to the effects of the α-adrenoceptor
agonists hampering a straightforward interpretation of these
data. Importantly, the present data indicate that clenbuterol, a
preferential β2-adrenoceptor agonist with approximately
tenfold higher affinity for β2-adrenoceptors over β1-
adrenoceptors (Baker 2010), dose dependently decreased
premature responding at doses that did not significantly alter
the measures of somatomotor activity. Moreover, in contrast
to the high-dose clenbuterol, the intermediate 0.03 mg/kg
dose improved visuospatial attention by increasing accurate
choice without simultaneous deteriorative effects on omis-
sions or response latencies (Fig. 5f). Thus, in extension to
beneficial effects on working memory (Ramos et al. 2008),
enhancing the tone at β2-adrenoceptors also improved
inhibitory response control. An important point of consider-
ation is that in addition to the beneficial behavioural effects
of particularly clenbuterol observed here, β2-adrenoceptors
and also β1-adrenoceptors are heavily implicated in cardiac
function (Brodde and Michel 1999). Indeed, clenbuterol has
been shown to exert myotoxic and potent haemodynamic
effects in rats starting at doses of 0.1 mg/kg (Burniston et al.
2002; Sillence et al. 1993). Although in the current study,
lower doses of clenbuterol were employed (0.01 and
0.03 mg/kg) we cannot entirely rule out that these same
doses affected cardiac function.
Similar to clenbuterol, the β1-adrenoceptor agonist
dobutamine increased visuospatial attention. Nonetheless,
thiseffectwasonlyobservedatthe highest doseof6.0 mg/kg.
Although dobutamine has an approximately tenfold higher
affinity for β1-adrenoceptors over β2-adrenoceptors
(Williams and Bishop 1981), it is possible that at this
dose the beneficial effects of this drug on visuospatial
attention are mediated through β2-adrenoceptor activation
(Baker 2010;M a k h a ya n dO ’Donnell 1999). At the same
time, it should be noted that these beneficial effects on
attention were not accompanied by significant improvements
of inhibitory control. Thus, whereas β1-adrenoceptor activa-
tionwas previouslyfound toimpair working memory(Ramos
et al. 2005), we did not find evidence for similar effects on
attention and inhibitory response control. Collectively, the
observation that dobutamine and clenbuterol improved
visuospatial attention is consonant with the notion that
similar to α1-adrenoceptor activation (see above), enhancing
β-adrenoceptor activity tunes information processing pre-
sumably via subcortical and sensory cortical mechanisms
(Arnsten 2000;B e r r i d g ea n dW a t e r h o u s e2003).
Our understanding of the contribution of different β-
adrenoceptors in inhibitory response control is limited as yet.
Altogether, the present experiments with β-adrenoceptor
agonists further strengthen the notion of β2-adrenoceptor
and to a lesser extent β1-adrenoceptor improvement of
prefrontal executive function and in particular inhibitory
response control and visuospatial attention. In this respect, it
is of interest to note that intracranial clenbuterol injections
into the prefrontal cortex ameliorated working memory
performance in rats implicating a functional role for β2-
adrenoceptors in this brain region in prefrontal function
(Ramos et al. 2008). The current observations with β-
adrenoceptor agonists are somewhat at odds with the single
other study in this area reporting that propanolol attenuates
the detrimental effects of methylphenidate on inhibitory
response control (Milstein et al. 2010). Evidence from that
study suggests subcortical β-adrenoceptor modulation of
DA in the effects of methylphenidate, since cortical NA
depletion did not attenuate the effects methylphenidate.
Clearly, future studies including the effects of selective β-
adrenoceptor antagonists and employing intracranial
approaches are warranted to further unravel this.
In summary, the present data extend previous findings
and show that indirect as well as direct adrenoceptor
agonists improve inhibitory response control in the
5CSRTT. Although the observed inhibitory effects of most
direct α-adrenoceptor and β-adrenoceptor agonists on
impulsive action cannot be interpreted unambiguously, our
findings with the β2-adrenoceptor agonist clenbuterol—
and to a lesser extent the β1-adrenoceptor agonist dobut-
amine—are consistent with a prominent role of noradren-
ergic neurotransmission in inhibitory response control. This
corroborates the notion that the central noradrenergic
system is involved in optimizing behavioural responses
including executive cognitive functioning (for reviews, see,
Psychopharmacology (2012) 219:327–340 337e.g. Aston-Jones and Cohen 2005;S a r a2009)a n d
particularly points to a role of β2-adrenoceptors therein.
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